RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteCancer Hospital, Shandong First Medical University山东省肿瘤医院JinanHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07798947, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed unresectable limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemotherapy and radiation therapy.

    Inclusion criterion 3

  3. Female trial participants of childbearing potential must agree to use highly effective contraception from the time of signing the informed consent form until 6 months after the last dose of the investigational drug, and avoid donating eggs.

    Inclusion criterion 7

    History of other malignancies within 5 years prior to the first dose of the study drug.

    Exclusion criterion 2

    Undergone major organ surgery within 4 weeks prior to the first dose of the study drug.

    Exclusion criterion 11

  4. ECOG performance status score of 0 or 1.

    Inclusion criterion 4

  5. Active tuberculosis infection within 1 year prior to enrollment, identified by medical history or imaging examination.

    Exclusion criterion 7

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07798947, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntarily participate in this clinical study, understand the study procedures, and be able to sign the informed consent form (ICF) in writing.
  • Aged 18 to 75 years (inclusive), of any gender.
  • Histologically or cytologically confirmed unresectable limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemotherapy and radiation therapy.
  • ECOG performance status score of 0 or 1.
  • Estimated survival time of more than 3 months.
  • Have adequate bone marrow and organ function.
  • Female trial participants of childbearing potential must agree to use highly effective contraception from the time of signing the informed consent form until 6 months after the last dose of the investigational drug, and avoid donating eggs.

Exclusion Criteria:

  • Combined small cell lung cancer or any transformed small cell lung cancer.
  • History of other malignancies within 5 years prior to the first dose of the study drug.
  • Severe cardiovascular or cerebrovascular diseases.
  • Bleeding symptoms of significant clinical relevance within 3 months prior to the first dose of the study drug.
  • Malignant pleural effusion or malignant pericardial effusion.
  • Severe infection within 4 weeks prior to the initiation of study treatment.
  • Active tuberculosis infection within 1 year prior to enrollment, identified by medical history or imaging examination.
  • History of immunodeficiency.
  • Active, known, or suspected autoimmune disease, or a history of autoimmune disease.
  • Prior treatment with immune checkpoint inhibitors (ICIs).
  • Undergone major organ surgery within 4 weeks prior to the first dose of the study drug.
  • Any other factors that, in the judgment of the investigator, may affect the study results or force premature termination of the study.

Quoted from ClinicalTrials.gov, NCT07798947, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07798947, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07798947